Shares of Vascular Solutions Inc. (NASDAQ:VASC) have been assigned an average rating of “Buy” from the six brokerages that are currently covering the stock. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $51.33.

Several research analysts have commented on VASC shares. Zacks Investment Research downgraded Vascular Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Sidoti downgraded Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 price target on the stock. in a research report on Tuesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating on shares of Vascular Solutions in a research report on Wednesday, August 10th. Needham & Company LLC started coverage on Vascular Solutions in a research report on Thursday. They issued a “buy” rating and a $58.00 price target on the stock. Finally, TheStreet raised Vascular Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 25th.

Vascular Solutions (NASDAQ:VASC) traded up 2.59% during midday trading on Thursday, reaching $48.33. The company’s stock had a trading volume of 119,382 shares. Vascular Solutions has a 1-year low of $24.34 and a 1-year high of $50.72. The firm has a 50 day moving average price of $48.46 and a 200 day moving average price of $41.41. The firm has a market capitalization of $845.34 million, a PE ratio of 89.50 and a beta of 0.54.

Vascular Solutions (NASDAQ:VASC) last issued its quarterly earnings results on Monday, July 25th. The medical device company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.03. The company had revenue of $41.20 million for the quarter, compared to the consensus estimate of $41.40 million. Vascular Solutions had a return on equity of 16.32% and a net margin of 6.22%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.29 EPS. On average, analysts predict that Vascular Solutions will post $1.24 EPS for the current year.

In other Vascular Solutions news, VP William Rutstein sold 10,011 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $46.26, for a total value of $463,108.86. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Howard Root sold 40,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $45.11, for a total value of $1,804,400.00. Following the completion of the sale, the chief executive officer now owns 347,840 shares in the company, valued at $15,691,062.40. The disclosure for this sale can be found here. 6.90% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Ruffer LLP boosted its stake in shares of Vascular Solutions by 22.2% in the first quarter. Ruffer LLP now owns 55,000 shares of the medical device company’s stock worth $1,790,000 after buying an additional 10,000 shares during the period. Menta Capital LLC acquired a new position in Vascular Solutions during the first quarter worth approximately $320,000. Mckinley Capital Management LLC Delaware acquired a new position in Vascular Solutions during the first quarter worth approximately $2,590,000. Prudential Financial Inc. raised its position in Vascular Solutions by 3.7% in the first quarter. Prudential Financial Inc. now owns 42,347 shares of the medical device company’s stock worth $1,378,000 after buying an additional 1,500 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its position in Vascular Solutions by 5.7% in the second quarter. Eagle Asset Management Inc. now owns 246,900 shares of the medical device company’s stock worth $10,285,000 after buying an additional 13,346 shares in the last quarter. Hedge funds and other institutional investors own 82.08% of the company’s stock.

Vascular Solutions Company Profile

Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.

5 Day Chart for NASDAQ:VASC

Receive News & Stock Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related stocks with our FREE daily email newsletter.